Consolidated Balance Sheet Detail

9 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Consolidated Balance Sheet Detail

Note 4. Consolidated Balance Sheet Detail

Inventory

The following table summarizes inventory by category for the dates presented:

	December 31, 2022		March 31, 2022
Raw materials	$	5,271	$	10,228
Work in progress		2,648		7,154
Finished goods		6,408		4,654
Total inventories	$	14,327	$	22,036

Inventory at December 31, 2022 included $1,611 of raw materials, $833 of work in progress and $3,413 of finished goods related to the MosaiQ project. Inventory at March 31, 2022, included $6,761 of raw materials, $4,252 of work in progress and $2,758 of finished goods related to the MosaiQ project. During the nine month period ended December 31, 2022, the Company recorded a write-off of $9.7 million in inventory and a $5.1 million write-off of prepaid assets related to the transfusion related MosaiQ assets. Included in other accrued expenses at December 31, 2022, is $140 of projected losses on firm purchase commitments recorded in other accrued expenses.

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following:

	December 31,  2022		March 31,  2022
Accrued legal and professional fees	$	2,426	$	1,254
Accrued interest		4,156		9,235
Goods received not invoiced		1,755		1,304
Accrued capital expenditure		124		193
Other accrued expenses		4,556		3,743
Total accrued expenses and other current liabilities	$	13,017	$	15,729